Business Context and Reporting Period
This Form 8-K Current Report was filed by Intrepid Potash, Inc. (NYSE: IPI) on July 24, 2020, with a report date of July 30, 2020. The filing addresses a notice of delisting received from the New York Stock Exchange (NYSE) and the results of a special stockholder meeting held on July 28, 2020.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and listing compliance matters.
Material Changes and Events
- NYSE Delisting Notice: On July 24, 2020, the Company received notice from the NYSE that it failed to comply with Section 802.01C of the Listed Company Manual, which requires an average closing share price of at least $1.00 over 30 consecutive trading days.
- Stock Designation: The Company's stock will continue to trade on the NYSE under the symbol "IPI" but will carry a ".BC" designation indicating below compliance status during the cure period.
- Shareholder Approval: Stockholders approved a reverse stock split with a ratio between 1-for-3 and 1-for-15. They also approved conditional reductions in authorized shares to 80,000,000, 40,000,000, or 26,666,667, depending on the split ratio implemented.
- Voting Results: Of 132,951,858 shares outstanding, 118,486,241 were represented. Proposal 1 (Reverse Split) received 113,015,625 votes for, 5,308,518 against, and 162,098 abstentions.
Outlook, Risks, and Management Commentary
- Cure Period: The Company has a six-month period to regain compliance with the minimum share price requirement. Compliance can be achieved if the closing share price is at least $1.00 on the last trading day of any calendar month during the cure period, along with a 30-day average of at least $1.00.
- Operational Impact: Management states the notice does not affect ongoing business operations, SEC reporting requirements, or trigger violations of material debt obligations.
- Delisting Risk: If the Company fails to regain compliance during the cure period, its common stock will be subject to NYSE suspension and delisting procedures.
- Strategic Options: In addition to the approved reverse split, the Company intends to consider all available options to cure the deficiency.
Investor Verification Checklist
- Verify the exact reverse stock split ratio and effective date once determined by the Board of Directors.
- Monitor the daily closing share price to assess progress toward the $1.00 minimum requirement during the six-month cure period.
- Confirm the final reduction in authorized shares following the implementation of the reverse split.
- Review the attached press release (Exhibit 99.1) for additional details on the Company's strategy to restore compliance.